Avost - Travoprost | VetSafeCare.Com

Brand

Avost

Travoprost — Ibn Sina Pharmaceuticals Ltd.
0% / ophthalmic solution

Alternatives

8

Routes

OPH

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Ophthalmic Solution · 0% / ophthalmic solution

3 ml

৳470

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Use in adults: The recommended dose is one drops of Travoprost in the conjunctival sac of the affected eye (s) once daily in the evening, If more than one topical ophthalmic product is being used, the medicines must be administered at least 5 minutes apart. When substituting another ophthalmic antiglaucoma agent with Travoprost, discontinue the other agent and start the following day with Travoprost.Pediatric patients: The efficacy and safety of travoprost eye drops in patients below the age of 18 years have not been established.

Clinical notes

Applications:

N/A

Indication Notes:
Travoprost Eye Drops is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of or insufficiently responsive to another intraocular pressure lowering medication, as monotherapy or as adjunctive therapy.
Avoid In:

N/A

Contraindication Notes:
Travoprost eye drops is contraindicated in patients with hypersensitive to travoprost or any excipients of this preparation.
Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
Reduced therapeutic effect with NSAIDs.
The most frequently reported treatment-related side-effect is ocular hyperaemia.
There are no adequate and well-controlled clinical study En pregnant women. Travoprost should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when travoprost is administered to a lactating woman.
Travoprost should be used with caution in patients with active intraocular inflammation (iritis/uveitis). Travoprost should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of Travoprost.